Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ef g

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    60 result(s) found for: Ef g. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-004333-33 Sponsor Protocol Number: 13HH1771 Start Date*: 2014-01-20
    Sponsor Name:Imperial College London
    Full Title: Phase 1 of dose escalation of extracorporeal shockwave treatment only and in combination DPP-4 inhibitor and parathyroid hormone (non-randomised, open-labelled) & Phase II of combination treatments...
    Medical condition: ischaemic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10077980 Chronic systolic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-005326-38 Sponsor Protocol Number: DIGIT-HF Start Date*: 2015-03-19
    Sponsor Name:Hannover Medical School
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to demonstrate that digitoxin reduces a composite of overall mortality and hospitalization for worsening heart failure in patients ...
    Medical condition: Advanced systolic chronic heart failure NYHA class III-IV and EF ≤ 40% or NYHA class II and EF ≤ 30%
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003235-31 Sponsor Protocol Number: Prof. Franz Weidinger Start Date*: 2005-01-31
    Sponsor Name:Div. of Cardiology, Innsbruck Medical University
    Full Title: Effect of pravastatin or fluvastatin and add-on valsartan on inflammatory markers and peripheral endothelial function in patients with acute coronary syndrome
    Medical condition: Acute coronary syndrome; patients with NSTEMI
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003858-85 Sponsor Protocol Number: HFIRONT Start Date*: 2020-02-24
    Sponsor Name:Medical University Innsbruck
    Full Title: Randomized double-blind explorative controlled clinical trial analyzing the effects of ferric carboxymaltose in patients with iron deficiency and chronic heart failure
    Medical condition: This is a randomized double-blind explorative controlled clinical Trial that analyses the effects of 1000mg ferric carboxymaltose in patients with chronic heart failure and iron deficiency.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001578-27 Sponsor Protocol Number: ABX464-302 Start Date*: 2019-10-15
    Sponsor Name:Abivax
    Full Title: A follow-up Phase 2a open-label study to evaluate the long-term safety and efficacy profile of ABX464 in patients with moderate to severe active Rheumatoid Arthritis.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007407-86 Sponsor Protocol Number: LevoRep Start Date*: 2009-09-14
    Sponsor Name:Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin III
    Full Title: Efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure
    Medical condition: Chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000733-14 Sponsor Protocol Number: DAPA-HD Start Date*: 2022-07-18
    Sponsor Name:Medical University of Vienna
    Full Title: SGLT2 INHIBITION (DAPAGLIFLOZIN) IN DIABETIC AND NON-DIABETIC HEMODIALYSIS PATIENTS WITH AND WITHOUT RESIDUAL URINE VOLUME: A PROSPECTIVE RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PHASE II TRIAL
    Medical condition: Cardiovascular Outcome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001772-38 Sponsor Protocol Number: G112 Start Date*: 2013-06-29
    Sponsor Name:A.N.M.C.O.-Fondazione Italiana lotta Malattie Cardiovasc
    Full Title: STEM-AMI OUTCOME TRIAL STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial
    Medical condition: Patients with left ventricular systolic disfunction after revascularization for acute myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005724-10 Sponsor Protocol Number: SPIHF-201 Start Date*: 2016-06-07
    Sponsor Name:Stealth BioTherapeutics Inc.
    Full Title: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart...
    Medical condition: Stable Heart Failure with Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001820-36 Sponsor Protocol Number: CAMG334AES01 Start Date*: 2019-08-13
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 12-month prospective, phase IIIb, multicenter, open-label clinical trial to assess health-related quality of life (HRQoL) in patients with chronic or high-frequency episodic migraine treated with...
    Medical condition: Study of Quality of life in subjects with chronic or high-frequency episodic migraine and associated comorbidities treated with erenumab
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004337-25 Sponsor Protocol Number: H6D-MC-LVHR Start Date*: 2009-01-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment o...
    Medical condition: Benign prostatic hyperplasia and erectile dysfunction.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061461 LLT
    9.1 10004446 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed) PT (Completed) DE (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003941-34 Sponsor Protocol Number: 22021980 Start Date*: 2008-02-11
    Sponsor Name:Vorstand des Klinikums der Universität München - Grosshadern
    Full Title: SAFETY AND EFFICACY OF SITAGLIPTIN PLUS GRANULOCYTE-COLONY STIMULATING FACTOR IN PATIENTS SUFFERING FROM ACUTE MYOCARDIAL INFARCTION - SITAGRAMI-Trial
    Medical condition: Patients undergoing routine percutaneous coronary revascularisation for acute ST segment elevation myocardial infarction (STEMI, time from onset of infarction to intervention 2 to 24 hours)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002852-17 Sponsor Protocol Number: SSH-IC Start Date*: 2020-06-02
    Sponsor Name:Marta Cobo Marcos
    Full Title: Efficacy and Safety of Intravenous Furosemide administered with Hypertonic Saline Solution at the Heart Failure Day Hospital. SSH-IC study
    Medical condition: Decompensated Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002995-13 Sponsor Protocol Number: S28720 UZ KUL Start Date*: 2006-01-23
    Sponsor Name:UZLeuven
    Full Title: An open label Phase II trial to investigate the cardiac effects of pegylated liposomal doxorubicine (Caelyx) in elderly breast cancer patients with new imaging and biochemical techniques.
    Medical condition: histologically proven early breast cancer requiring adjuvant chemotherapy according to the treating physician (lymph node positive or other features of high risk according to St-Gallen criteria). 1...
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002336-17 Sponsor Protocol Number: REDUCe_2017-05-22 Start Date*: 2017-08-06
    Sponsor Name:Department of Clinical Sciences, Danderyd Hospital, Karolinska Intitutet
    Full Title: Randomized Evaluation of Decreased Usage of betablocCkErs after myocardial infarction in the SWEDEHEART registry REDUCe SWEDEHEART
    Medical condition: Long-term treatment with beta-blockers in patients with myocardial infarction and preserved ejection fraction.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019224-31 Sponsor Protocol Number: IGR2009/1593 Start Date*: 2012-06-06
    Sponsor Name:Institut Gustave Roussy
    Full Title: INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTS
    Medical condition: untreated advanced stage B-cell NHL or B-AL.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006595 Burkitt's lymphoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067194 Burkitt's leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Temporarily Halted) NL (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020122-18 Sponsor Protocol Number: BAY 98-7081/14694 Start Date*: 2010-07-23
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to va...
    Medical condition: Erectile dysfunction
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061461 Erectile dysfunction LLT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) FI (Completed) ES (Completed) IT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000486-29 Sponsor Protocol Number: GIM9 (NEO-ADIXERN) Start Date*: 2008-06-03
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: A feasibility study of dose-dense FEC wiith G-CSF support followed by dose-dense Ixabepilone wiith G-CSF support as neoadjuvant chemotherapy in ER- negative breast cancer
    Medical condition: In ER-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004333-57 Sponsor Protocol Number: N01221 Start Date*: 2015-02-10
    Sponsor Name:UCB Japan Co., Ltd.
    Full Title: A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam used as add-on Therapy at doses of 0.5 to 3 g/day in Patients From 1...
    Medical condition: Epilepsies Partial
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001508-45 Sponsor Protocol Number: TTD-16-02 Start Date*: 2016-09-19
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: Phase II clinical trial to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphisms
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 06:02:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA